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Levosimendan in septic shock in patients with biochemical evidence of cardiac dysfunction 
– a subgroup analysis of the LeoPARDS randomised trial. 
 
 
Methods 
Inclusion Criteria 
The target population was adult patients (≥18 years) who required vasopressor support for 
the management of sepsis despite fluid resuscitation. Inclusion criteria used the 
internationally established consensus definitions of sepsis at that time [1]. 
 
• Fulfil 2/4 of the criteria of the systemic inflammatory response syndrome 
(SIRS) due to known or suspected infection within the previous 24 hours.  
The SIRS criteria were: 
(1) fever (>38 °C) or hypothermia (< 36 °C), 
(2) tachycardia (heart rate > 90 beats per minute), 
(3) tachypnoea (respiratory rate > 20 breaths per minute or PaCO2 < 4.3 kPa) 
or need for mechanical ventilation, 
(4) abnormal leukocyte count (> 12,000 cells/mm3, < 4000 cells/mm3, or > 
10% immature [band] forms). 
 
• Hypotension, despite adequate intravenous fluid resuscitation, requiring treatment with a 
vasopressor infusion (e.g. noradrenaline / adrenaline / vasopressin analogue) for at least four 
hours and still having an ongoing vasopressor requirement at the time of randomisation. 
Adequate fluid resuscitation was achieved using repeated fluid challenges.  
 
Exclusion Criteria 
• More than 24 hours since meeting all the inclusion criteria 
• End-stage renal failure at presentation (previously dialysis-dependent) 
• Severe chronic hepatic impairment (Child-Pugh class C) 
• A history of Torsades de Pointes 
• Known significant mechanical obstructions affecting ventricular filling or outflow or both. 
• Treatment limitation decision in place (eg Do Not Attempt Resuscitation or not for 
ventilation/ dialysis) 
• Known or estimated weight >135kg 
• Known to be pregnant 
• Previous treatment with levosimendan within 30 days 
• Known hypersensitivity to levosimendan or any of the excipients 
• Known to have received another investigational medicinal product within 30 days or 
currently in another interventional trial that might interact with the study drug. 
 
Missing data 
The calculation of the mean daily SOFA score requires a total SOFA score for each day the 
patient is in ICU, with the total SOFA being the sum of five components. 
The proportion of daily scores that were missing was 6.2% overall. By component, 2.3% of 
scores were missing for the cardiovascular system, 3.9% for respiratory, 5.1% for renal, 12.8% 
for hepatic and 6.8% for coagulation. The clinical expectation was that measurements may 
not be taken if there was no change. Therefore, we imputed values using last observation 
carried forward as planned. The primary outcome was imputed as follows. Where there were 
only one or two consecutive days missing, or where the missing data occurred at the end of 
the ICU admission, SOFA scores were imputed using last observation carried forward. If the 
first day was missing the value from day two was taken, and if these were both missing the 
baseline value was taken. Where there were three or more days missing, the average value 
of the last available and next available observation was used as the imputed value.  
 
Modelling biomarker trajectories 
Bayesian hierarchical regression models were used to evaluate whether biomarker 
trajectories differed for patients receiving levosimendan compared to those in the placebo 
group.  Assuming a biomarker B follows a log-normal distribution, and assuming a linear 
change over time, we specified the model as follows: 
 
 
 
The following vague prior distributions were used: 
 
 
 
 
Where Bit is the biomarker value for patient i at time t (t=0,1,2 corresponding to days 2, 4 
and 6 post randomisation respectively), Bbi is the biomarker value for patient i at baseline, 
and trti is the treatment indicator for patient i (0=placebo, 1=levosimendan), and Ui is a 
patient-specific random intercept. We presented an estimate of the mean treatment 
difference at each time point t, given by β2 +β4 ×t with 95% credible intervals, and the 
probability that NT-pro BNP reduces faster in Levosimendan patients compared to placebo, 
given by Pr(β4 < 0).  
 
Any values below/above the limits of detection were treated as missing, but arising from the 
same distribution as the observed values truncated at the limit of detection. In contrast to 
using a fixed value falling below/above the limit, this approach acknowledges uncertainty in 
the values. We used two chains with diffuse starting values and checked convergence using 
trace plots and the Gelman-Rubin convergence statistic. After convergence, Markov Chain 
Monte Carlo simulations were run until the effective sample size was around 10,000. 
 
Results 
Additional results for biomarker analysis  
Table S1 to S7 show the full results from the hierarchical regression models for cardiovascular 
biomarkers and inflammatory mediators. Here all results are provided, including models without 
the treatment x time interaction, along with those for sensitivity analyses adjusting for age and 
APACHE II score, and for ICU effects. The Deviance Information Criterion (DIC) is included as a 
measure of model fit. The model with the smallest DIC is considered to fit the data best, though 
alternative models with a difference of less than 3 should not be ruled out, and differences of less 
than 7 indicate weak support for the “best” model. 
 
  
Table S1: Full results for longitudinal models for troponin I (cTnI) 
 Main model No interaction Adjusting for age 
and APACHE II 
Adjusting for ICU 
effects 
Change per day - 
Levosimendan  
0.87 (0.74,1.01) 
0.80 (0.72,0.89) 
0.87 (0.74,1.01) 0.87 (0.74,1.01) 
Change per day - Placebo  0.75 (0.65,0.86) 0.75 (0.64,0.86) 0.75 (0.64,0.86) 
Pr(faster reduction in 
Levosimendan)  
0.082  0.081 0.082 
Treatment difference on day 2  1.12 (0.79,1.55) 
1.26 (0.92,1.67) 
1.14 (0.81,1.58) 1.12 (0.78,1.55) 
Treatment difference on day 4  1.30 (0.95,1.73) 1.33 (0.98,1.77) 1.30 (0.95,1.73) 
Treatment difference on day 6  1.52 (1.01,2.19) 1.56 (1.03,2.25) 1.52 (1.01,2.21) 
Change per:      
10% increase in baseline cTnI  1.03 (1.02,1.04) 1.03 (1.02,1.04) 1.03 (1.02,1.03) 1.03 (1.02,1.04) 
1 year increase in age    1.01 (1.00,1.02)  
Unit increase in APACHE II 
score  
  1.05 (1.03,1.07)  
Random effects variance:      
Patient intercept  1.70 (1.37,2.07) 1.69 (1.37,2.06) 1.63 (1.31,1.98) 1.69 (1.36,2.05) 
ICU intercept     0.03 (0.00,0.13) 
DIC  4104.3 4106.0 4094.7 4104.9 
 
  
Table S2: Full results for longitudinal models for NT-pro BNP 
 Main model No interaction Adjusting for age 
and APACHE II 
Adjusting for ICU 
effects 
Change per day - 
Levosimendan  
1.09 (1.00,1.19) 
 
1.02 (0.96,1.09) 
1.09 (1.00,1.19) 1.09 (1.00,1.19) 
Change per day - Placebo  0.97 (0.90,1.05) 
 
0.97 (0.90,1.05) 0.97 (0.90,1.06) 
Pr(faster reduction in 
Levosimendan)  
0.032  0.032 0.035 
Treatment difference on day 2  1.00 (0.84,1.19) 
1.10 (0.94,1.27) 
1.01 (0.84,1.20) 1.00 (0.84,1.19) 
Treatment difference on day 4  1.12 (0.96,1.30) 1.13 (0.97,1.31) 1.12 (0.96,1.30) 
Treatment difference on day 6  1.26 (1.02,1.54) 1.27 (1.02,1.56) 1.26 (1.02,1.54) 
Change per:      
10% increase in baseline NT-
pro BNP  
1.07 (1.06,1.07) 1.07 (1.06,1.07) 1.07 (1.06,1.07) 1.07 (1.06,1.07) 
1 year increase in age    1.00 (0.99,1.01)  
Unit increase in APACHE II 
score  
  1.01 (1.00,1.02)  
Random effects variance:      
Patient intercept  0.36 (0.27,0.46) 0.36 (0.27,0.46) 0.36 (0.27,0.46) 0.35 (0.26,0.45) 
ICU intercept     0.01 (0.00,0.05) 
DIC  2723.1 2725.4 2720.8 2723.3 
 
  
Table S3: Full results for longitudinal models for CCL2 
 Main model No interaction Adjusting for age 
and APACHE II 
Adjusting for ICU 
effects 
Change per day - 
Levosimendan  
0.78 (0.73,0.83) 
0.74 (0.71,0.77) 
0.78 (0.73,0.83)  0.76 (0.71,0.81)   
Change per day - Placebo  0.71 (0.66,0.75) 0.71 (0.66,0.75)  0.71 (0.66,0.75)   
Pr(faster reduction in 
Levosimendan)  
0.019  0.018  0.079   
Treatment difference on day 2  0.89 (0.78,1.02) 
0.96 (0.86,1.07) 
0.89 (0.78,1.02)  0.86 (0.76,0.97)   
Treatment difference on day 4  0.98 (0.87,1.10) 0.98 (0.88,1.10)  0.92 (0.84,1.00)   
Treatment difference on day 6  1.08 (0.92,1.26) 1.08 (0.92,1.26)  0.98 (0.85,1.13)   
Change per:         
10% increase in baseline CCL2  1.05 (1.04,1.06) 1.05 (1.04,1.06) 1.05 (1.04,1.05)  1.05 (1.04,1.06)   
1 year increase in age    1.00 (0.99,1.00)     
Unit increase in APACHE II 
score  
  1.01 (1.00,1.02) 
    
Random effects variance:      
Patient intercept  0.22 (0.17,0.27) 0.22 (0.17,0.27) 0.21 (0.16,0.27)  0.19 (0.14,0.24)   
ICU intercept      0.02 (0.00,0.06)   
DIC  2186.4 2191.9 2182.0  2204.0  
 
  
Table S4: Full results for longitudinal models for IL6 
 Main model No interaction Adjusting for age 
and APACHE II 
Adjusting for ICU 
effects 
Change per day - 
Levosimendan  
0.50 (0.44,0.56)  
0.50 (0.46,0.54)  
0.50 (0.44,0.56)  0.50 (0.44,0.56)  
Change per day - Placebo  0.50 (0.45,0.56)  0.50 (0.45,0.56)  0.50 (0.45,0.56)  
Pr(faster reduction in 
Levosimendan)  
0.536   0.532  0.552  
Treatment difference on day 2  1.00 (0.79,1.25)  
0.99 (0.82,1.20)  
1.01 (0.79,1.26)  1.01 (0.80,1.25)  
Treatment difference on day 4  0.99 (0.81,1.20)  1.00 (0.82,1.20)  1.00 (0.83,1.19)  
Treatment difference on day 6  0.99 (0.74,1.29)  1.00 (0.75,1.30)  0.99 (0.75,1.28)  
Change per:      
10% increase in baseline IL6  1.04 (1.03,1.04)  1.04 (1.03,1.04)  1.04 (1.03,1.04)  1.04 (1.03,1.04)  
1 year increase in age    1.00 (0.99,1.01)   
Unit increase in APACHE II 
score  
  1.02 (1.00,1.03)   
Random effects variance:      
Patient intercept  0.54 (0.39,0.70)  0.54 (0.39,0.70)  0.53 (0.39,0.70)  0.44 (0.30,0.60)  
ICU intercept     0.10 (0.03,0.21)  
DIC  3462.2  3459.7  3459.3  3452.3  
 
  
Table S5: Full results for longitudinal models for IL8 
 Main model No interaction Adjusting for age 
and APACHE II 
Adjusting for ICU 
effects 
Change per day - 
Levosimendan  
0.85 (0.80,0.91)  
0.82 (0.79,0.86)  
0.85 (0.80,0.91)  0.85 (0.80,0.91)  
Change per day - Placebo  0.80 (0.75,0.84)  0.79 (0.75,0.84)  0.79 (0.75,0.84)  
Pr(faster reduction in 
Levosimendan)  
0.046   0.048  0.048  
Treatment difference on day 2  1.00 (0.85,1.17)  
1.06 (0.91,1.22)  
1.00 (0.85,1.17)  1.00 (0.86,1.17)  
Treatment difference on day 4  1.08 (0.93,1.24)  1.08 (0.93,1.25)  1.08 (0.94,1.24)  
Treatment difference on day 6  1.16 (0.97,1.38)  1.16 (0.97,1.38)  1.16 (0.97,1.38)  
Change per:      
10% increase in baseline IL8  1.05 (1.05,1.06)  1.05 (1.05,1.06)  1.05 (1.05,1.06)  1.06 (1.05,1.06)  
1 year increase in age    1.00 (0.99,1.00)   
Unit increase in APACHE II 
score  
  1.02 (1.01,1.03)   
Random effects variance:      
Patient intercept  0.48 (0.40,0.58)  0.48 (0.40,0.57)  0.47 (0.39,0.56)  0.44 (0.36,0.52)  
ICU intercept     0.05 (0.01,0.11)  
DIC  2112.6  2115.7  2109.0  2108.9  
 
  
Table S6: Full results for longitudinal models for IL10 
 Main model No interaction Adjusting for age 
and APACHE II 
Adjusting for ICU 
effects 
Change per day - 
Levosimendan  
0.68 (0.63,0.73)  
0.69 (0.65,0.72)  
0.68 (0.63,0.73)  0.68 (0.63,0.73)  
Change per day - Placebo  0.69 (0.65,0.74)  0.69 (0.65,0.74)  0.69 (0.65,0.74)  
Pr(faster reduction in 
Levosimendan)  
0.662   0.644  0.671  
Treatment difference on day 2  1.06 (0.90,1.25)  
1.05 (0.91,1.20)  
1.07 (0.91,1.25)  1.07 (0.91,1.25)  
Treatment difference on day 4  1.04 (0.90,1.19)  1.05 (0.91,1.20)  1.05 (0.91,1.20)  
Treatment difference on day 6  1.02 (0.85,1.23)  1.03 (0.85,1.23)  1.02 (0.85,1.23)  
Change per:      
10% increase in baseline IL10  1.04 (1.04,1.05)  1.04 (1.04,1.05)  1.04 (1.04,1.05)  1.04 (1.04,1.05)  
1 year increase in age    1.00 (1.00,1.01)   
Unit increase in APACHE II 
score  
  1.02 (1.01,1.03)   
Random effects variance:      
Patient intercept  0.38 (0.30,0.47)  0.38 (0.30,0.47)  0.37 (0.29,0.45)  0.36 (0.28,0.44)  
ICU intercept     0.02 (0.00,0.06)  
DIC  2450.2  2447.0  2443.8  2449.4  
 
  
Table S7: Full results for longitudinal models for sTNFr1 
 Main model No interaction Adjusting for age 
and APACHE II 
Adjusting for ICU 
effects 
Change per day - 
Levosimendan  
0.90 (0.86,0.93)  
0.90 (0.87,0.92)  
0.90 (0.86,0.93)  0.89 (0.86,0.93)  
Change per day - Placebo  0.90 (0.86,0.93)  0.89 (0.86,0.93)  0.90 (0.86,0.93)  
Pr(faster reduction in 
Levosimendan)  
0.500   0.492  0.513  
Treatment difference on day 2  1.02 (0.93,1.12)  
1.02 (0.94,1.11)  
1.02 (0.93,1.12)  1.02 (0.93,1.12)  
Treatment difference on day 4  1.02 (0.94,1.11)  1.02 (0.94,1.11)  1.02 (0.94,1.11)  
Treatment difference on day 6  1.02 (0.92,1.13)  1.02 (0.92,1.14)  1.02 (0.92,1.13)  
Change per:      
10% increase in baseline 
sTNFr1  
1.08 (1.07,1.08)  1.08 (1.07,1.08)  1.08 (1.07,1.08)  1.08 (1.07,1.08)  
1 year increase in age    1.00 (1.00,1.00)   
Unit increase in APACHE II 
score  
  1.01 (1.00,1.01)   
Random effects variance:      
Patient intercept  0.14 (0.11,0.17)  0.14 (0.12,0.17)  0.14 (0.11,0.17)  0.13 (0.11,0.16)  
ICU intercept     0.17 (0.00,0.03)  
DIC  1174.1  1171.6  1172.1  1173.1  
 
 
 
  
Figure S1 Boxplot of troponin I values by timepoint of sampling comparing those receiving 
levosimendan (red boxes) or placebo (green boxes). Day 1 was prior to randomisation on day 
of inclusion and day 2 after 24 hours of treatment. The number of patients sampled on each 
day on intensive care are given below the figure. 
 
 
 
  
Day of study 
Figure S2 Boxplot of NT-proBNP values by timepoint of sampling comparing those receiving 
levosimendan (red boxes) or placebo (green boxes). Day 1 was prior to randomisation on day 
of inclusion and day 2 after 24 hours of treatment. The number of patients sampled on each 
day on intensive care are given below the figure. 
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Figure S3 Boxplots of a CCL2 b IL10 c IL6 d IL8 and e sTNFr1 measurements by timepoint of 
sampling comparing those receiving levosimendan (red boxes) or placebo (green boxes). Day 
1 was prior to randomisation on day of inclusion and day 2 after 24 hours of treatment. The 
number of patients sampled on each day on intensive care are given below the figure. 
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